ChemBriefTakeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
A U.S. jury found Takeda liable for $885 million in damages for delaying the generic release of its constipation drug Amitiza via an anticompetitive scheme. This marks the first time a drugmaker was h
reuters · 2026-05-18 11:53